Moderna to take next step with vaccine candidate against rare disease
Interim data from a phase I/II study shows the candidate has been well-tolerated.
by christian bundgaard, translated by daniel pedersen
Moderna is a step closer to its ambition of developing and providing vaccines for rare diseases after presenting interim phase I/II data for a new candidate.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA panel backs Pfizer's maternal RSV vaccine
For subscribers
Bavarian Nordic closes vaccine portfolio acquisition
For subscribers
